The Journal of Heart and Lung Transplantation
Volume 29, Issue 5 , Pages 562-567 , May 2010

Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts

References 

  1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report—2006. J Heart Lung Transplant. 2006;25:869–879
  2. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation. 1997;96:2069–2077
  3. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res. 1997;80:607–616
  4. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology (XXIII. The angiotensin II receptors). Pharmacol Rev. 2000;52:415–472
  5. Yousufuddin M, Cook DJ, Starling RC, et al. Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. J Am Coll Cardiol. 2004;43:1565–1573
  6. Yousufuddin M, Haji S, Starling RC, et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J. 2004;25:377–385
  7. Yamani MH, Cook DJ, Rodriguez ER, et al. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant. 2006;25:1283–1289
  8. Yamamoto T, Sata M, Fukuda D, et al. The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy. J Surg Res. 2006;132:62–68
  9. Richter M, Skupin M, Grabs R, et al. New approach in the therapy of chronic rejection? (ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model). J Heart Lung Transplant. 2000;19:1047–1055
  10. Yamamoto T, Sata M, Fukuda D, et al. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Res Cardiol. 2005;100:84–91
  11. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054–2057
  12. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126–3132
  13. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol. 2001;21:372–377
  14. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105:1240–1246
  15. Yuan Z, Liu Y, Zhang J, et al. Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res. 2003;59:685–694
  16. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897–1905
  17. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–1371
  18. Marx N, Schonbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097–1103
  19. de Dios ST, Bruemmer D, Dilley RJ, et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 2003;107:2548–2550
  20. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235–238
  21. Wang N, Verna L, Chen NG, et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 2002;277:34176–34181
  22. Kosuge H, Haraguchi G, Koga N, et al. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation. 2006;113:2613–2622
  23. Isobe M, Haber E, Khaw BA. Early detection of rejection and assessment of cyclosporine therapy by indium-111 antimyosin imaging in mouse heart allografts. Circulation. 1991;84:1246–1255
  24. Suzuki J, Cole SE, Batirel S, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant. 2003;3:968–976
  25. Eich DM, Nestler JE, Johnson DE, et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 1993;87:261–269
  26. Shimizu K, Schönbeck U, Mach F, et al. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 2000;165:3506–3518
  27. Corthorn J, Rey S, Chacon C, et al. Spatio-temporal expression of MMP-2, MMP-9 and tissue kallikrein in uteroplacental units of the pregnant guinea-pig (Cavia porcellus). Reprod Biol Endocrinol. 2007;5:27
  28. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–899
  29. Zezina L, Larsson E, Fellstrom B. Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. Transplant Immunol. 2001;8:245–251
  30. Tsuda M, Iwai M, Li JM, et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005;45:545–551
  31. Furukawa Y, Mandelbrot DA, Libby P, et al. Association of B7-1 co-stimulation with the development of graft arterial disease (Studies using mice lacking B7-1, B7-2, or B7-1/B7-2). Am J Pathol. 2000;157:473–484
  32. Zheng XX, Gao W, Donskoy E, et al. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation. 2006;81:109–116
  33. Tsukioka K, Suzuki J, Fujimori M, et al. Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res. 2002;56:472–478

PII: S1053-2498(09)00850-X

doi: 10.1016/j.healun.2009.11.001

The Journal of Heart and Lung Transplantation
Volume 29, Issue 5 , Pages 562-567 , May 2010

Article Tools

* Image Usage & Resolution